MARKET

PGEN

PGEN

Precigen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.530
+0.210
+4.86%
After Hours: 4.520 -0.01 -0.22% 17:38 07/10 EDT
OPEN
4.350
PREV CLOSE
4.320
HIGH
4.590
LOW
4.170
VOLUME
987.78K
TURNOVER
--
52 WEEK HIGH
8.70
52 WEEK LOW
1.260
MARKET CAP
774.69M
P/E (TTM)
-4.0174
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PGEN stock price target is 9.33 with a high estimate of 13.00 and a low estimate of 7.00.

EPS

PGEN News

More
Preclinical Data for PRGN-3005 UltraCAR-T® Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T
PR Newswire · 06/22 13:45
Precigen to Participate in Upcoming JMP Securities Hematology and Oncology Forum
PR Newswire · 06/11 12:30
Billionaire Israel Englander Bets on These 3 Penny Stocks
TipRanks · 06/10 14:35
Notice: Precigen Announces Date and Location Change for its 2020 Annual Meeting of Shareholders
PR Newswire · 06/04 21:05
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenax Therapeutics Inc (NASDAQ: TENX) shares climbed 42.3% to $2.07 after the company reported results from its Phase 2 trial of Levosimendan. The trial demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures.
Benzinga · 06/02 16:21
Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T at the AACR Virtual Annual Meeting II in June 2020
PR Newswire · 05/15 12:30
Biotech Stock Rally Is Crushing Short Sellers
Benzinga’s Take Biotech stocks are often high-risk, high-reward investments that have binary outcomes based on one or a handful of drug or device candidates in development. Shorting these types of stocks can be very risky due to the potential for unexpec
Benzinga · 05/11 16:15
H.C. Wainwright Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $5
H.C. Wainwright initiates coverage on Precigen (NASDAQ:PGEN) with a Buy rating and announces Price Target of $5.
Benzinga · 05/08 14:42

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About PGEN

Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
More

Webull offers kinds of Precigen Inc stock information, including NASDAQ:PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.